TauRx nabs $112M to back Phase III Alzheimer's program
Nov 20 - 2012 02:56 PM
Prepping for an ambitious late-stage program to test its experimental Alzheimer's therapy, TauRx says it has banked a $31.5 million tranche from Malaysia's Genting Management, part of a $112 million commitment for the biotech upstart. TauRx says the rest of the money should arrive before the end of the year.
Rogue researcher offers new hope for sufferers of Alzheimer's disease
Nov 10 - 2012 08:45 AM
Approximately 36 million people worldwide suffer from Alzheimer's disease or dementia.
BioClinica Signs Agreements with TauRx for a Series of Expanded Trials
Nov 07 - 2012 02:45 PM
Earlier this week, a global provider of clinical trial management solutions, BioClinica, Inc., announced that in order to use Trident IWR/IVR and Imaging Core Lab (ICL) solutions to support its upcoming Phase III clinical trials, TauRx Therapeutics has signed agreements with BioClinica.
Zillion Magazine (December 2014) - 'A Novel Approach to Alzheimer's Disease'
Oct 30 - 2012 03:11 PM
TauRx Chairman Claude Wischik was interviewed by Zillion, an Amsterdam-based publication, about the Phase III clinical trials (see the article below).
Das blaue Wunder Das blaue Wunder
Aug 28 - 2008 07:00 AM
Ein alter Farbstoff soll die Alzheimersche Krankheit lindern. Die Fachwelt rätselt, ob es sich um eine Ente handelt - oder um eine sensationelle Entdeckung